TY - JOUR
T1 - Shaping the future of biomarker research in breast cancer to ensure clinical relevance
AU - Hinestrosa, M. Carolina
AU - Dickersin, Kay
AU - Klein, Pamela
AU - Mayer, Musa
AU - Noss, Karin
AU - Slamon, Dennis
AU - Sledge, George
AU - Visco, Frances M.
N1 - Funding Information:
The National Breast Cancer Coalition Fund (NBCCF) thanks the Strategic Consensus Conference panelists, the conference planning committee and, in particular, the consumers and scientists that worked on a pre-conference Lessons Learned Research Project: D. Berry, C. Brunswick, K. Dickersin, H. Hill, M. Mayer, H. Schiff and J. Perlmutter. The Strategic Consensus Conference was made possible thanks to generous funding provided by the Regis Foundation for Breast Cancer Research, the Virginia Clinton Kelley Fund of the NBCCF, the Doris Duke Charitable Foundation and Hurricane Voices.
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/4
Y1 - 2007/4
N2 - Each year, over 200,000 people are diagnosed with breast cancer in the United States. Although the use of biomarkers has the potential to guide preventive interventions and improve survival and quality of life, there have been few successes and many disappointments. In November 2005, the National Breast Cancer Coalition Fund convened a conference aimed at developing a patient-centred, strategic approach to breast cancer biomarker research. The consumers, clinicians, researchers, industry representatives and US regulators who served on the consensus panel developed a set of principles and recommendations to guide the field and ensure that biomarker research results in clinically important applications.
AB - Each year, over 200,000 people are diagnosed with breast cancer in the United States. Although the use of biomarkers has the potential to guide preventive interventions and improve survival and quality of life, there have been few successes and many disappointments. In November 2005, the National Breast Cancer Coalition Fund convened a conference aimed at developing a patient-centred, strategic approach to breast cancer biomarker research. The consumers, clinicians, researchers, industry representatives and US regulators who served on the consensus panel developed a set of principles and recommendations to guide the field and ensure that biomarker research results in clinically important applications.
UR - http://www.scopus.com/inward/record.url?scp=33947576553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947576553&partnerID=8YFLogxK
U2 - 10.1038/nrc2113
DO - 10.1038/nrc2113
M3 - Review article
C2 - 17384585
AN - SCOPUS:33947576553
SN - 1474-175X
VL - 7
SP - 309
EP - 315
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 4
ER -